Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

SURGEONS SHOULD NOT OPERATE ON INGROWING TOENAILS

7th Congress of the European Federation of National Associations of Orthopaedics and Traumatology, Lisbon - 4-7 June, 2005



Abstract

Introduction: We present the results of a prospective randomized trial of Zadik’s procedure V. chemical ablation by sodium hydroxide for the treatment of ingrowing toenails.

Materials and Methods: Thirty eight patients had Zadik’s procedure, 45 patients had chemical ablation by sodium hydroxide. Mean average follow-up was 12.45 months for Zadik’s group and 11.69 months for the chemical group.

Results: We have studied 5 end points: 1/return to normal shoe wear. In Zadik’s group, the average return to normal shoe wear was 2.13 weeks and 3.73 weeks in the chemical group. 2/average return to normal activity was 2.18 weeks for Zadik’s group and 3.89 for the chemical group. 3/the median numbers of dressings were 3 and 8 for Zadik’s and chemical ablation patients respectively. 4/the pain score, using the visual analogue, were not statistically significant between the two groups. 5/the recurrence rate, 23 recurrences in Zadik’s group (60.5%) and seven recurrences in chemical ablation group (15.6%). However, only 13 patients had symptomatic recurrence (34.2%) in the Zadik group and two patients had recurrence in the chemical ablation group (4.4%).

Conclusion: The use of chemical ablation by sodium hydroxide in the treatment of ingrowing toenails shows statistically significant reduction in the recurrence rate of ingrowing toenails compared to Zadik’s procedure (P< 0.05). Key words: Ingrowing toe nails, Zadik’s, Chemical ablation.

Theses abstracts were prepared by Professor Roger Lemaire. Correspondence should be addressed to EFORT Central Office, Freihofstrasse 22, CH-8700 Küsnacht, Switzerland.